Literature DB >> 18006961

A newborn with spinal muscular atrophy type 0 presenting with a clinicopathological picture suggestive of myotubular myopathy.

Amelie Nadeau1, Guy D'Anjou, Guillaume Debray, Yves Robitaille, Louise R Simard, Michel Vanasse.   

Abstract

We report a male term newborn with genetically confirmed spinal muscular atrophy type 0, presenting with arthrogryposis and severe generalized weakness and requiring ventilatory support. Muscle biopsy revealed fibers with central nuclei resembling myotubes and negative myotubularin immunohistochemical staining compared with a control muscle biopsy. The absence of myotubularin associated with survival motor neuron protein deficiency suggests that survival motor neuron protein may have a role in muscle fiber maturation and myotubularin expression. Studying the pathology of this rare and lethal neonatal form of spinal muscular atrophy may further our understanding of spinal muscular atrophy pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006961     DOI: 10.1177/0883073807307105

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  New therapeutic approaches to spinal muscular atrophy.

Authors:  Aga Lewelt; Tara M Newcomb; Kathryn J Swoboda
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

2.  SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

Authors:  Kathryn J Swoboda
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

3.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.

Authors:  Shingo Kariya; Teresa Obis; Caterina Garone; Turgay Akay; Fusako Sera; Shinichi Iwata; Shunichi Homma; Umrao R Monani
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 4.  Spinal muscular atrophy: journeying from bench to bedside.

Authors:  Tomoyuki Awano; Jeong-Ki Kim; Umrao R Monani
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.

Authors:  Shingo Kariya; Gyu-Hwan Park; Yuka Maeno-Hikichi; Olga Leykekhman; Cathleen Lutz; Marc S Arkovitz; Lynn T Landmesser; Umrao R Monani
Journal:  Hum Mol Genet       Date:  2008-05-20       Impact factor: 6.150

6.  Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond.

Authors:  Umrao R Monani; Darryl C De Vivo
Journal:  Future Neurol       Date:  2014-01-01

Review 7.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

8.  Survival analysis of spinal muscular atrophy type I.

Authors:  Hyun Bin Park; Soon Min Lee; Jin Sung Lee; Min Soo Park; Kook In Park; Ran Namgung; Chul Lee
Journal:  Korean J Pediatr       Date:  2010-11-30

Review 9.  New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?

Authors:  Tai-Heng Chen
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.